MSLN and pancreatic neoplasm: The main targets of CAR-T therapy for solid tumors include ganglioside GD2 in neuroblastoma, mesothelin in pancreatic cancer, carcinoembryonic antigen in CRC, fibroblast activation protein in malignant pleural mesothelioma, and epidermal growth factor receptor in non-small cell lung cancer 29.